Skip to main content
Menu

Posts tagged with "Clinical Trials"

  • Alzheimer's Disease

    More, Unfortunately, on the Chinese Alzheimer’s Drug Approval

    I wrote yesterday about the surprise decision by the Chinese regulators to allow a new Alzheimer’s drug on the market. That drug (GV-971) was developed by Green Valley Pharmaceuticals, a company (and a drug, for that matter) that frankly I had never heard of. But other people have heard of both, and they’ve been contacting… Read More
  • Alzheimer's Disease

    A New Alzheimer’s Approval in China

    Edit: tomorrow’s post will be on this subject too, with some information that I’ve been learning today. . . Today brought the rather surprising news that the Chinese government’s National Medical Product Administration (NMPA) has approved a new Alzheimer’s drug. What’s more, it’s an unusual (and unexpected) mecha… Read More
  • Alzheimer's Disease

    The Return of Aducanumab

    When last heard from, Biogen and Eisai’s aducanumab (another amyloid-targeting antibody for Alzheimer’s) had failed in Phase III and the whole effort was being terminated. Then came Tuesday. Biogen then startled everyone by announcing that a review of the clinical data had convinced them that the drug had actually worked – or at l… Read More
  • Clinical Trials

    An AI-Generated Drug?

    There were some headlines the other day about the “first AI-discovered drug”, so that should send us to the work in question to see what’s going on. The company in question is called Deep Genomics, and here’s what its founder has to say: “Making drugs has traditionally been a gambling game. Big Pharma is throwing… Read More
  • Clinical Trials

    Adaptive Trials

    There are a lot of clinical trial designs out there. But one thing that a lot of them have in common is that they are designed right from the start to run under certain set conditions and to enroll a set number of people (or at least to meet certain thresholds before that enrollment is… Read More
  • Clinical Trials

    What’s Crucial And What Isn’t

    One of the reasons that people in or near this business can write such gaudy press releases is that it has so many moving parts. That lets everyone claim that the part that they’re addressing is Crucial. Think of a car: the wheels are indeed key to mobility, but so is the engine. As is… Read More
  • Clinical Trials

    Quietly Another Drug Candidate Disappears

    I wanted to note something today that won’t make many headlines outside of biopharma, but it’s just the sort of story that I wish more people knew about. Let’s start with this: there’s a terrible disease called IPF, idiopathic pulmonary fibrosis. Anyone with any medical background knows to beware the word “idiopathic&# Read More
  • Cancer

    Your Cancer Targets May Not Be Real

    I wrote here about a paper from Cold Spring Harbor labs that invalidated MELK as a cancer target. That was straightforward enough: knocking it out via CRISPR across a whole range of cancer cell lines had no effect on their growth at all, so it’s kind of hard to make the case that it’s an… Read More
  • Clinical Trials

    Stopping Early

    There was a mention yesterday in the comments section about a clinical trial that was stopped early due to efficacy. I’ve never been involved with a project that this has happened to myself – pretty much the opposite, for the most part! – but it does happen, and is generally cause for celebration. Although not… Read More
  • Clinical Trials

    An Awful Idea: Paying to Get Into a Clinical Trial

    This article at Stat by Rebecca Robbins really caught me eye. It describes clinical trials where the participants are being asked to pay thousands of dollars just to join the trial. There seems to have been an increase in this sort of thing lately, and I’ll be completely clear: I think that’s a terrible idea… Read More
123...